Draupnir Bio
Pioneering the next frontier of extracellular protein degradation
Founded 2017 · $35.0M raised
- Founded
- 2017
- Business Model
- B2B
- Website
- draupnir.bio
- Total Funding
- $35.0M
- Last Round
- $35.0M Series A
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Draupnir Bio is a biotechnology company developing oral small-molecule degraders that extend targeted protein degradation to extracellular and membrane-bound proteins, which first-generation TPD approaches leave untouched. The company is a spin-out from Aarhus University in Denmark and the Max-Planck Society in Germany, based in Copenhagen with research operations in Aarhus, and is backed by Gilde Healthcare Partners, Inkef Capital, Novo Seeds, MP Healthcare Venture Management and EIFO. Its proprietary platform targets lysosome receptors and is being used to build a risk-diversified preclinical pipeline against validated and historically hard-to-drug targets. Draupnir Bio was founded in April 2017.
Summary
Draupnir Bio is a Biotech company, founded in 2017. It has raised $35.0M in total across 1 round. Investors include Novo Seeds, Gilde Healthcare and Inkef.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Investors
Similar Companies
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/draupnir-bio"><img src="https://indexed.vc/api/badge/company/draupnir-bio" alt="Draupnir Bio on Indexed.vc" width="260" height="76" /></a>